Patty Baskin
Executive Editor, Neurology®
pbaskin@aan.com
(612) 928-6021
Exam: Exam 137
Issue: July 3, 2012
Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis
Upon completion of this podcast, the participant will be able to discuss the potential risks of thrombolytic therapy for stroke patients on subtherapeutic warfarin.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.
Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.
Dr. Burns receives a stipend as Podcast Editor for Neurology® and performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc. AAN staff members editing the test (P Baskin, L Kleffman) have no disclosures. The CME Journal Editors, who have reviewed the exam, are Steven Lewis MD, who receives a stipend in his editorial capacity for Neurology, and James WM Owens Jr. MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology.
Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders. Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society. Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.
The other participants had nothing to disclose.
CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.
The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.
The American Academy of Neurology holds copyright for all materials in this exam.
Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.
A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.